Amneal FDA Friday, November 30, 2018 -0.30 Negative

FDA Approves LAMOTRIGINE — Amneal Pharmaceuticals LLC

Amneal Pharmaceuticals received FDA approval November 30 for the Abbreviated New Drug Application for Lamotrigine tablets, positioning the company to capture market share in the generic antiepileptic landscape. This clearance expands Amneal’s generic portfolio and threatens to drive down prices for the widely used seizure medication.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed